Li D, Duan Q, Weinkauf J, et al. - In lung transplant recipients, the composite endpoint of death or chronic lung allograft dysfunction (CLAD) onset are reported to reduce in correlation with using azithromycin prophylaxis (AP; this was defined as chronic use of azithromycin initiated prior to CLAD onset). In this study, researchers evaluated the correlation between AP and survival, the risk of CLAD and baseline lung allograft dysfunction (BLAD). They assessed 445 double lung recipients transplanted. Of these, 344 (77%) received AP [median time from transplant 51 days]. Outcomes revealed correlation of receiving azithromycin prophylaxis with enhanced survival after lung transplantation, potentially through improved baseline function. These findings build on prior trial results and indicate the benefits of AP for lung transplant recipients.